Group A received nasogastric feeding (NG), insure through ngt pump

receive feeding throughThe nasojejunal tube is silicone or polyurethane tube with an inner stylet that is positioned (under fluoroscopic guidance) beyond the ligament of Treitz.
Patients were placed in right lateral position

Postoperative Nausea

• The insertion of NG tubes were performed by the ICU physician and the position was checked by auscultation of gas from 50 ml syringe by injecting 20 ml of air in the NG and by X-ray abdomen to be sure from the site of NG tube

nasogastric

The nasojejunal tube is silicone or polyurethane tube with an inner stylet that is positioned (under fluoroscopic guidance) beyond the ligament of Treitz.
Patients were placed in right lateral position

nasojejunal

prokinetic (erythromycin 250 mg IV bolus) given to assist the passage of the tube through the pylorus

(erythromycin 250 mg IV bolus)

King abd el Aziz specialist hospital

Entral Feeding in Acute Severe Pancreatitis

Comparative Study Between Different Methods of Enteral Feeding in Acute Severe Pancreatitis

first pillar comparing the effect of the two enteral feeding methods on the clinical condition of the acute severe pancreatitis,The second pillar include effect of the two enteral feeding methods on the patient's tolerance

King Abdul Aziz Specialist Hospital

COVID

GastroMuñoz

COVID-EC Study: Clinical Characteristics of Patients With COVID-19 in Guayaquil, Ecuador

Clinical Characteristics of Patients With SARS-CoV-2 (COVID-19) Infection in Guayaquil, Ecuador: COVID-EC Study

To know the clinical characteristics of patients with COVID-19 treated in hospitals in Guayaquil, Ecuador.

Establish the prognosis of patients, in terms of need for admission to intensive care, use of mechanical ventilation or death.

To determine the clinical characteristics of the patients with the worst prognosis.

Relate, at least retrospectively, the relationship that may exist between the different treatments and the prognosis.

Jorge Carriel M.

Physician

Hospital San Carlos, Madrid

Universidad Catolica Santiago de Guayaquil

The group of 50 patients are going to receive Chlorpromazine (oral dose of 50 mg/ day for 3 days then doubled to 100mg/day for further 11 days) every 24 hours for 14 days in addition to the convential treatment of COVID-19 according to the Egyptian Ministry of Health protocol.

A group of 50 patients control group who will recieve only the convential treatment of COVID-19 according to the Egyptian Ministry of Health protocol.

COVID-19

(Oral dose of 50 mg/ day for 3 days then doubled to 100mg/day for further 11 days)

Chlorpromazine

Cairo University

Administration of Chlorpromazine as a Treatment for COVID-19

In the current study, the clinical improvement will be determined by:
Temperature
Heart rate (pulse)
Respiratory rate
Oxygen saturation
Need for oxygen
Hospital stay time.
CT lung involvement at day 0 and day 14.

Ahmed Rezk

Clinical Instructor

Noha Mahmoud Nasreldin Hassan

Single centred, single-blinded randomised controlled trial. All subjects from a population of interest will be randomly assigned to one of two groups, one group who is exposed to the intervention or a second group who receive the routine care in the hospital.

The control group will be provided with a placebo medication of similar taste, color, texture, and consistency as the study medication, and will be dispensed once a day on Monday, Wednesday, and Friday.

Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will be not be adjusted if a new weight is obtained during the trial period.

The control group will be provided with a placebo medication of similar taste, color, texture, and consistency as the study medication. Patients will receive placebo at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.

Placebo

The azithromycin group will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.

Azithromycin

Total

Age, Customized

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

Region of Enrollment

Gestational Age

Number of Participants who Received Synagis Injection

Number of Patients with Tracheostomy

Participants were observed for a minimum of 5 months and a maximum of 8 months, depending on when study enrollment occurred. Patients were recruited for this study on a rolling basis during the start of the winter season and then completed the intervention at the same time at the end of the winter season, which accounts for the variability in the amount of time participants were observed.

Number of Unscheduled Face-to-face Physician Visits (Clinic Visits, ER Visits, and Hospitalizations)

Number of Adverse Events

Participants were observed for a minimum of 5 months and a maximum of 8 months, depending on when study enrollment occurred. Patients were recruited for this study on a rolling basis during the start of the winter season and then completed the intervention at the same time during the end of the winter season, which accounts for the variability in the amount of time participants were observed.

Healthcare Cost Associated With Respiratory Illness

To determine if prophylactic use of azithromycin will reduce the total number of unscheduled face-to-face physician visit for respiratory related illness in a clinic, urgent care, emergency room or hospital setting during the following 12 months after the intervention.

Long Term Reduction in Respiratory Symptoms

To determine if prophylactic use of azithromycin will reduce level of airway resistance as measured by an Airwave Oscillometry System in subjects above 2 years of age, at the time of respiratory illnesses, during the 3-6 months intervention.

Level of Airway Conductance

Using a standardize nasal wash procedure, respiratory samples will be collected at enrollment, at end of study, and during acute respiratory illness requiring face-to-face provider interaction. Children with a tracheostomy will have both a nasal wash sample and a tracheal aspirate sample collected. The respiratory samples will be stabilized with a universal transport media, processed and stored at -80 C for future testing. Testing will be performed for cytokines/chemokines; other biomarkers of disease such as LDH, MPO, and caspase; viral and bacterial respiratory pathogens; and microbiome.

Level of Cytokines

Overall Study

Ricardo A. Mosquera, MD

Chronic Lung Disease

Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.

Patients will receive placebo at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.

lactate dehydrogenase/diarrhea

Entral Feeding in Acute Severe Pancreatitis

COVID-EC Study: Clinical Characteristics of Patients With COVID-19 in Guayaquil, Ecuador

Administration of Chlorpromazine as a Treatment for COVID-19

The Anti-inflammatory Effect of Prophylactic Macrolides on Children With Chronic Lung Disease

Den mest komplette databasen med medisinske urter støttet av vitenskap